


PHARMACEUTICAL 2018



Sarepta Therapeutics Inc. Rank 54 of 349





PHARMACEUTICAL 2018



Sarepta Therapeutics Inc. Rank 54 of 349



The relative strengths and weaknesses of Sarepta Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sarepta Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 168% points. The greatest weakness of Sarepta Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 61% points.

The company's Economic Capital Ratio, given in the ranking table, is 72%, being 350% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	1,228,644
Cost of Goods Sold	0
Intangible Assets	14,355
Liabilities, Current	88,332
Liabilities, Non-Current	5,539
Other Assets	21,809
Other Compr. Net Income	-259
Other Expenses	38,893
Other Liabilities	424,876
Other Net Income	123,010
Property and Equipment	43,156
Research and Development	166,707
Revenues	154,584
Selling, General and Administrative Expense	122,682

Output Variable	Value in 1000 USD
Assets	1,307,964
Liabilities	518,747
Expenses	328,282
Stockholders Equity	789,217
Net Income	-50,688
Comprehensive Net Income	-50,818
Economic Capital Ratio	72%